Page 106 - Memoria FEHH - SEHH 2017

PROGRAMA ESPAÑOL DE TRATAMIENTOS EN HEMATOLOGÍA (PETHEMA)
MEMORIA ANUAL 2017
SOCIEDAD ESPAÑOLA FUNDACIÓN ESPAÑOLA
DE HEMATOLOGÍA Y HEMOTERAPIA DE HEMATOLOGÍA Y HEMOTERAPIA
• Paiva B, Puig N, Cedena MT, Cordón L, Vidriales MB, Burgos L, Flores-Montero J, López-Anglada L, Gutiérrez N, Ca- lasanz MJ, Martín-Ramos ML, García-Sanz R, Martínez-López J, Oriol A, Blanchard MJ, Ríos R, Martín J, Martínez R, Sarrà J, Hernández MT, de la Rubia J, Krsnik I, Moraleda JM, Palomera L, Bargay J, Orfao A, Rosiñol L, Mateos MV, Lahuerta JJ, Bladé J, San Miguel JF. Impact of the next generation flow (NGF) Minimal Residual Disease (MRD) monitoring in Multiple Myeloma (MM): Results from Pethema/GEM2012 Trial. 59th ASH Annual Meeting. Atlanta, December 2017. Blood. 2017;130:905.
• Lonial S, San-Miguel JF, Martínez-López J, Mateos MV, Bladé J, Benboubker L, Oriol A, Arnulf B, Chari A, Pineiro L, Jianping Wang KW, Doshi P, Schecter J, Moreau P. Daratumumab in Combination with Carfilzomib and Dexa- methasone in Patients (pts) with Relapsed Multiple Myeloma (MMY1001): an Open-Label, Phase 1b Study. 59th ASH Annual Meeting. Atlanta, December 2017. Blood. 2017;130:1869.
• Mateos MV, Goldschmidt H, San-Miguel JF, Mikhael J, De-Costa L, Zhou L, Obreja M, Blaedel J, Szabo Z, Leleu X.
Carfilzomib in Relapsed or Refractory Multiple Myeloma Patients with Early or Late Relapse Following Prior Therapy: A Subgroup Analysis of the Randomized Phase 3 Aspire and Endeavor Trials. 59th ASH Annual Meeting. Atlanta, December 2017. Blood. 2017;130:3120.
• Ocio EM, Motllo C, Rodríguez Otero P, Martínez López J, de la Rubia J, Martín J, Bladé J, García Malo MD, Palomera L, García Mateo A, De Arriba F, García Sanz R, Oriol A, Lahuerta JJ, San Miguel JF, Mateos MV. Safety and Efficacy of Filanesib in Combination with Pomalidomide and Dexamethasone in Refractory MM Patients. Phase Ib/II Pomdefil Clinical Trial Conducted By the Spanish MM Group. 59th ASH Annual Meeting. Atlanta, December 2017. Blood. 2017;130:1873.
• Dimopoulos MA, Laubach J, Echeveste Gutiérrez MA, Grzasko N, Hofmeister CC, San Miguel JF, Kumar S, Lu V, Teng Z, Liu G, Byrne C, Berg D, Labotka R, van de Velde H, Richardson PG. Efficacy and Safety of Long-Term Ixazo- mib Maintenance Therapy in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Not Undergoing Transplant: An Integrated Analysis of Four Phase 1/2 Studies. 59th ASH Annual Meeting. Atlanta, December 2017. Blood. 2017;130:902.
• Ocio EM, Puig N, Corchete L, Pérez JJ, Dávila J, Paíno T, de la Rubia J, Oriol A, Martín J, De Arriba F, Bladé J, Blan- chard MJ, García Sanz R, Paiva B, Lahuerta JJ, San Miguel JF, Mateos MV. Immune Predictors of Response to Pembrolizumab Monotherapy As Consolidation in Multiple Myeloma Patients: Results of the GEM-Pembresid Clinical Trial. 59th ASH Annual Meeting. Atlanta, December 2017. Blood. 2017;130:1874.
• Mateos MV, Martínez López J, Rodríguez-Otero P, Ocio EM, González MS, Oriol A, Gutiérrez N, Paiva B, Ríos R, Ro- sinol L, Álvarez MA, Calasanz MJ, Bargay J, González AP, Escalante F, Martínez R, Puig N, de la Rubia J, Teruel AI, Cedena MT, De Arriba F, Palomera L, Hernández MT, López Jiménez J, Martín J, Piensa E, García Mateo A, González V, Bladé J, Lahuerta JJ, San Miguel JF. Curative Strategy for High-Risk Smoldering Myeloma (GEM-CESAR): Carfilzomib, Lenalidomide and Dexamethasone (KRd) As Induction Followed By HDT-ASCT, Consolidation with Krd and Maintenance with Rd. 59th ASH Annual Meeting. Atlanta, December 2017. Blood. 2017;130:402.
• Medina A, Jiménez C, Puig N, Sánchez Vega B, Flores Montero J, González M, Calasanz MJ, Ayala RM, Sarasquete ME, Paiva B, Cedena MT, Fernández Mercado M, Rapado I, Rosinol L, Ocio EM, Oriol A, Alcoceba M, Hernández MT, Martínez Martínez R, Mateos MV, Lahuerta JJ, Bladé J, Orfao A, San Miguel JF, Martínez-López J, García-Sanz R. New Alternatives for the Evaluation of Minimal Residual Disease (MRD) Detection By Next Generation Sequencing in Multiple Myeloma. 59th ASH Annual Meeting. Atlanta, December 2017. Blood. 2017;130:1783.
• Leivas A, Valeri A, Río P, Fernández L, Pañero I, Lee DA, Powell Jr. DJ, Lahuerta JJ, Pérez Martínez A, Martínez-López J. Activated and Expanded Natural Killer Cells Expressing an NKG2D-CAR Efficiently Target Multiple Myeloma Cells. 59th ASH Annual Meeting. Atlanta, December 2017. Blood. 2017;130:4466.
106